Scarica l'app Stockscreener
6.56
5.61%
-0.39
Dopo l'orario di chiusura:
7.00
0.44
+6.71%
Precedente Chiudi:
$6.95
Aprire:
$6.82
Volume 24 ore:
441.10K
Relative Volume:
0.69
Capitalizzazione di mercato:
$313.36M
Reddito:
-
Utile/perdita netta:
$-59.85M
Rapporto P/E:
-7.4066
EPS:
-0.8857
Flusso di cassa netto:
$-54.54M
1 W Prestazione:
-7.74%
1M Prestazione:
-7.21%
6M Prestazione:
+221.57%
1 anno Prestazione:
+442.15%
Intervallo 1D:
$6.42
$7.22
Intervallo di 1 settimana:
$6.42
$7.46
Portata 52W:
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
6.56 | 313.36M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | B. Riley Securities | Buy |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-03-05 | Iniziato | Wedbush | Outperform |
| 2026-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | William Blair | Outperform |
| 2025-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Robert W. Baird | Outperform |
| 2025-06-06 | Iniziato | Oppenheimer | Outperform |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - minichart.com.sg
Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com
Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - Bitget
Climb Bio Consolidates Financial Leadership After SVP Departure - TipRanks
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
If You Invested $1,000 in Climb Bio (CLYM) - Stock Titan
Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia
Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):